

### In the Claims

Please amend the claims as follows.

1. (Amended) A method to ~~modulate fibrous tissue formation comprising administering to an individual in need of treatment thereof an effective amount of a dermatan sulfate or chondroitin sulfate degrading enzyme~~ of using a glycosaminoglycan-degrading enzyme to reduce a cell proliferative response comprising  
administering an effective amount of the enzyme to an individual in need thereof,  
wherein the enzyme removes dermatan sulfate or chondroitin sulfate from cell surfaces  
thereby effectively decreasing growth factor receptors on the cell surfaces, and  
wherein decreasing the growth factor receptors thereby decreases the cell proliferative response to such growth factors.
2. (Original) The method of claim 1 wherein the enzyme is selected from the group consisting of bacterial dermatan or chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aureescens*, arylsulfatase B, N-acetylgalactosamine-6-sulfatase and iduronate sulfatase from mammalian cells, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.
3. (cancelled)
4. (Original) The method of claim 1 wherein the enzyme is a bacterial enzyme.
5. (Amended) The method of claim 4 wherein the ~~chondroitinase~~ enzyme is chondroitinase B.
6. (Amended) The method of claim 1 wherein the ~~individual has a skin disorder~~ enzyme is administered to decrease fibroblast proliferation.

7. (Amended) The method of claim 6 1 wherein the skin disorder is ~~scleroderma or psoriasis~~ chondroitin sulfate is selected from the group consisting of chondroitin sulfate B, chondroitin sulfate A and chondroitin sulfate C.

8. (Amended) The method of claim 1 wherein the individual has ~~keloid~~ scarring or is at risk of ~~keloid~~ scarring, ~~or has pulmonary fibrosis.~~

9. (Original) The method of claim 1 wherein the enzyme is administered systemically.

10. (Original) The method of claim 1 wherein the enzyme is administered topically or locally at or adjacent to a site in need of treatment.

11. (Original) The method of claim 1 wherein the enzyme is administered in a controlled and/or sustained release formulation.

12. (Amended) A formulation for administration to an individual in need of treatment thereof for a ~~disorder involving organ fibrosis~~ reducing a cell proliferative response, the formulation comprising an effective amount of a ~~dermatan or chondroitin sulfate~~ glycosaminoglycan degrading enzyme to inhibit ~~fibrosis~~ the cell proliferative response, wherein the dosage is different than the amount effective for wound healing, and a pharmaceutically acceptable carrier.

13. (Original) The formulation of claim 12 wherein the enzyme is selected from the group consisting of bacterial chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aurescens*, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.

14. (cancelled)

15. (Original) The formulation of claim 12 wherein the enzyme is a bacterial chondroitinase.

16. (Original) The formulation of claim 15 wherein the chondroitinase is chondroitinase B.
17. (Original) The formulation of claim 12 wherein the enzyme is in a controlled, sustained release formulation.
18. (Amended) The formulation of claim 12 in a dosage effective to reduce collagen synthesis.
19. (Amended) The formulation of claim 12 in an effective ~~aerosol~~ formulation for ~~delivery to the lungs~~ systemic administration.